Resource Search

Results: 336

The EPP Expert Board members read - and select - for you the ‘must’ read books, articles and whitepapers for pricing practitioners.  
EPP Connect&More is another great source for pricing professionals, managed by a team of industry contributors. 
* Sign-up to receive the free monthly EPP Connect&More : here
* Some content in the EPP Content database is reserved for EPP Members only ;  sign-up : here


New Price Models

C-level executives continue to consider pricing a top strategic priority, and for good reason: It’s the largest driver of growth in customers, revenue, and profits.

What’s helped some of today’s most successful companies flourish? A big factor is their pairing of innovative digital offerings with new price models that are fast becoming the focus in every industry B2C and B2B companies,especially some of the most successfulcompanies in media and technology.

  • Author(s): Accenture
  • Uploaded on: 08/02/2021
  • Content Type: Articles

Dynamic Pricing

C-level executives continue to consider pricing a top strategic priority, and for good reason: It’s the largest driver of growth in customers, revenue, and profits.

In the “old days,” pricing used to be largely a “set it and forget it” exercise. But not anymore. Automated price setting and more frequent price changes to best capture customers’ willingness-to-pay is today’s “holy grail” of pricing for most companies. Pioneered by airlines’ smart revenue management systems, dynamic pricing has gained prominence in many other settings — including hotels, ride hailing, e-commerce and, increasingly, traditional retail. 

  • Author(s): Accenture
  • Uploaded on: 08/02/2021
  • Content Type: Articles

BMS, Roche, AZ Lose Out as China Favors Domestic Companies in 2020 NRDL PD-1 Battle

In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL).

This year, PD-1 inhibitors — a category of drugs that are often costly yet highly effective — were the hot issue between multinational corporations (MNCs) and domestic businesses. When the negotiations came to a close, home-grown PD-1 efforts from Shanghai Junshi Biosciences, BeiGene Ltd. and Jiangsu Hengrui Medicine took the coveted spots from household names like Roche, Bristol Myers Squibb, AstraZeneca and MSD.

  • Author(s): EVERSANA - Pricentric ONE
  • Uploaded on: 22/02/2021
  • Content Type: Articles

Winning in Turbulent Times

In this whitepaper, Craig Zawada, Chief Visionary Officer of PROS, explains:

  • Why digital interactions are the new imperative
  • Where B2B companies fall short on digital strategies
  • The volatility trifecta
  • Recommendations to light up digital channels
  • Author(s): Craig Zawada, Chief Visionary Officer of PROS
  • Uploaded on: 16/02/2021
  • Content Type: Articles

The Pricing Revolution

C-level executives continue to consider pricing a top strategic priority, and for good reason: It’s the largest driver of growth in customers, revenue, and profits.

New global research from Accenture highlights the current state of pricing as well as where pricing is headed in the near future. They surveyed more than 500 C-level executives in companies with more than US$1 billion in revenue across 17 business-to-business (B2B) and business-to-consumer (B2C) industries in Europe, Asia, and America.

  • Author(s): Lena Chatchatrian
  • Uploaded on: 08/02/2021
  • Content Type: Articles

EPP Thought Leadership Series 1/2021

Edition 1/2021What CPQ Can Do for You

Over the last few years there has been a tremendous amount of buzz about CPQ software (Configure-Price-Quote).

According to Gartner,  the market for CPQ software grew 12.4% to $1.2b in 2018. Clearly this is an important investment area for many B2B companies. This whitepaper aims to help companies assess if CPQ solutions are right for them and how best to get started on the journey.

You will also find relevant insights from the latest EPP Global Pricing Survey: Pricer’s perspective of commercia lexecution.

The EPP® Thought Leadership Series provide insights from pricing leaders around the globe. When a new insight breaks, these pricing leaders already think of the unanswered questions and the story behind the story.  These people want to inspire you to act - to take the next step in your journey. With these series, we help to take the right actions

  • Author(s): Vendavo
  • Uploaded on: 03/01/2020
  • Content Type: Articles

Pricing Maturity Playbook - Crossing the pricing chasm

  • Author(s): Pol Vanaerde
  • Uploaded on: 08/01/2021
  • Content Type: Articles

How Does the Biden Administration Want to ‘Take on Pharma?’

  • Democratic President-elect Joe Biden and his administration are poised to take the reins from President Donald Trump, who had just begun to more stringently address prescription drug prices in the U.S. via Executive Orders (EOs) aimed at introducing an American version of reference pricing.
  • Throughout his campaign, Biden has promised to expand access to health care through the “BidenPlan,” an evolution of former President Barack Obama’s Affordable Care Act, dubbed “Obamacare,”while “taking on big pharma” and reining in “runaway” drug prices.
  • Biden has also announced intentions to set up a government-run, Institute for Clinical and Economic Review (ICER) -style Health Technology Assessment (HTA) body, as ICER is currently an autonomous body to the U.S. government
  • Author(s): EVERSANA - Pricentric ONE
  • Uploaded on: 16/12/2020
  • Content Type: Articles

Do Germany's New Hemophilia Regulations Have Wider-reaching Implications?

In July 2019, the Drug Safety and Supply Law (GSAV) was passed by Germany’s Higher Chamber of Parliament, bringing about substantial changes to Germany’s health policy.

Since the GSAV’s implementation in August of this year, the distribution, and consequently the pricing of hemophilia treatments in Germany have been subject to more regulation under the law.

In addition, the manufacturer’s ability to distribute directly to doctors and hospitals, avoiding the pharmacy distribution channel, was officially withdrawn, thereby allowing patients to receive their hemophilia products from regular pharmacies and ultimately meaning that manufacturers had to report their confidential sales prices to physicians.

  • Author(s): EVERSANA - Pricentric ONE
  • Uploaded on: 23/11/2020
  • Content Type: Articles

At the COVID-19 Finish Line, How Do We Price The Winning Vaccine?

As of August 21, 2020, there were more than 165 potential vaccine candidates in development for the novel coronavirus. While some are still in preclinical stages, a handful are quickly making their way toward regulatory approval, meaning that pricing is starting to become an urgent reality.

The first safety trials in humans started as early as March, due to various expedited clinical development processes in place around the globe that promised to bring a vaccine to fruition as quickly as 12 to 18 months from the outbreak of the pandemic—an unprecedented time frame that was quick to spark a reaction from critics.

But now, as the reality of a commercialized SARS-CoV-2 vaccine becomes closer every day, countries the world are over are starting to ink deals with various front running companies in order to ensure supply for their citizens when the time comes.

Dedicating budget and resources to finding and accessing a COVID-19 vaccine means that there will have to be trade-offs in other areas of healthcare, which could trickle down for years to come, so it’s important that government bodies and organizations get the best deal possible.

Some companies have already proposed potential vaccine prices, throwing out ballpark figures of anything from around $4 to $72 for a dose, calling into question how much we actually end up paying for a vaccine. 

  • Author(s): EVERSANA - Pricentric ONE
  • Uploaded on: 14/09/2020
  • Content Type: Articles